Current Market Position

On Wednesday, 21 March 2026, Nextcure (ticker NXTC) closed the trading day down 4.06 %, with a closing price of USD 5.70. At the time of reporting, the stock was being traded on a number of international exchanges, reflecting a broad base of global investors. The company’s total shares outstanding amount to 4.6 million, and the market capitalization currently stands at USD 26 million. In the past 24 hours, roughly USD 446.6 thousand worth of shares changed hands, indicating moderate liquidity for traders.

The company’s 200‑day simple moving average (SMA) sits at USD 8.16, a level that has historically served as a benchmark for long‑term investors. While the 52‑week high was USD 15.74 (recorded on 24 November 2025), the 52‑week low is a modest USD 1.55, reached on 26 June 2026. The relatively tight price range suggests that Nextcure’s stock has experienced a period of consolidation, with investors weighing the prospects of upcoming clinical milestones against the backdrop of a competitive biopharmaceutical landscape.

Recent Regulatory Filings

Nextcure’s latest disclosure to the U.S. Securities and Exchange Commission (SEC) is a Schedule 13G filed by JP Sailing Capital Ltd and Jianping Huang. The filing confirms that each party exerts effective control over 9.9 % of the company’s outstanding shares via their investment‑management arrangement with JP Sailing Fund. Importantly, the parties are not seeking to influence corporate control, and the shares are held in the ordinary course of business. The filing also clarifies that JP Sailing Capital is classified as a non‑U.S. investment adviser under Rule 13d‑1(b)(1)(ii)(J). No additional material events or financial performance data were disclosed.

Comparative Performance of Peer Securities

In the same 24‑hour window, several peers in the biopharmaceutical and technology sectors exhibited notable movements:

  • Gridai (GRDX): Up 5.47 %, now trading at USD 4.84. The company has a market capitalization of USD 31.1 million and has recently filed a registration statement for a resale offering of up to 9.9 million shares. Despite continued operating losses and a significant accumulated deficit, Gridai’s management projects that current cash and proceeds from private placements will support operations for about eighteen months.

  • Vivid Seats (SEAT): Up 1.45 %, trading at USD 2.79 with a market cap of USD 30.9 million.

  • Bridger Aerospace Hold (BAER): Up 7.59 %, now at USD 0.55 and a market cap of USD 30.3 million.

  • Virtra (VTSI): Down 1.87 %, trading at USD 2.61 and a market cap of USD 30.3 million.

  • Rave Restaurant (RAVE): Up 5.12 %, now at USD 2.20 with a market cap of USD 30.6 million. The restaurant’s price‑to‑earnings ratio stands at 10.75.

These movements underscore the volatility that can characterize the broader market for clinical‑stage and specialty companies, particularly when earnings data or regulatory milestones are pending.

Company Overview

Nextcure, Inc. is a clinical‑stage biopharmaceutical company headquartered in Beltsville, Maryland. The firm focuses on immunomedicines for cancer and other diseases, developing therapies that aim to harness the body’s immune system to fight malignancies. Its pipeline includes several investigational products at various phases of clinical development, with a particular emphasis on solid tumors and rare disease indications.

For investors seeking further information, Nextcure’s activities and latest updates are available on the company’s website at www.nextcure.com . Shares are listed on the Nasdaq stock exchange, allowing easy access for institutional and retail investors alike.

This article presents a concise snapshot of Nextcure’s recent market activity, regulatory filings, and peer performance, providing stakeholders with contextual insights to inform their investment decisions.